(Q24246409)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

1 reference

https://doi.org/10.1002/14651858.CD005413.pub3

1 reference

29 December 2023

http://retractionwatch.com/2010/09/20/progressive-how-the-cochrane-library-handles-updates-in-progress/

title

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

A D Sasse

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

E C Sasse

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

L G O Clark

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

O A C Clark

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

24 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

CD005413

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

A randomised trial of vindesine plus interferon-alpha 2b compared with interferon-alpha 2b or vindesine alone in the treatment of advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Docetaxel in combination with dacarbazine in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Metastatic melanoma: chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

The role of adjuvant therapy in melanoma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Systemic treatments for metastatic cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Immunotherapy of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Biochemotherapy for advanced melanoma: maybe it is real

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Recent declines in worldwide mortality from cutaneous melanoma in youth and middle age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Future perspectives on malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

Dysplastic nevi. Markers for increased risk for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

Systemic therapy in melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

An in vitro study on the effects of isoprinosine on immune responses in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

Biochemotherapy for advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

1 reference

7 January 2021

Interferon alpha-2a and dacarbazine in melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005413.PUB2

7 January 2021

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD005413.PUB2

Cancer statistics, 1995.

1 reference

30 December 2023

Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD005413.PUB2

Identifiers

DOI

10.1002/14651858.CD005413.PUB2

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17253556%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017